RxDoctor Payments Data

Ankit Shah, MD

Interventional Cardiology · Arlington Heights, ILNPI 1962426056

Payments from drug & device makers

$6,561in general payments, 2019–2025

Across 217 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1K
  • Novartis$768
  • Abbott$610
  • Edwards Lifesciences$308
  • Amgen$301
  • Merck$272
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,561 in reported general payments places this provider in the 40th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$266,753
Medicare patients
1,137
Services billed
2,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$541,997
XareltoRivaroxaban165$210,637
EntrestoSacubitril/Valsartan37$64,544
Repatha SureclickEvolocumab33$36,365
JardianceEmpagliflozin22$36,260
BrilintaTicagrelor24$21,421
FarxigaDapagliflozin Propanediol21$21,398
Praluent PenAlirocumab14$13,643
Atorvastatin Calcium932$9,455
Metoprolol Succinate607$8,796
Ranolazine ErRanolazine38$6,630
ClopidogrelClopidogrel Bisulfate441$5,380
Rosuvastatin Calcium284$4,706
Amlodipine Besylate571$4,508
Metoprolol Tartrate521$4,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$200$541,997437 claims
Johnson & JohnsonXarelto$193$210,637165 claims
NovartisEntresto$768$64,54437 claims
AstraZenecaBrilinta, Farxiga$134$42,81945 claims
Boehringer IngelheimJardiance$270$36,26022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →